Five Prime Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>FP</div>
FPRX -- USA Stock  

USD 5.35  0.22  3.95%

Five Prime Accounts Payable Turnover is fairly stable at the moment as compared to the past year. Five Prime reported Accounts Payable Turnover of 7.01 in 2019. Accrued Expenses Turnover is likely to rise to 0.80 in 2020, whereas Net Income Per Employee is likely to drop (1.6 M) in 2020. The upcoming quarterly report is expected on the 4th of November 2020. The stock experiences an active upward rally. Healthcare space may be getting hot again, let's check if Five Prime Therapeutics is sending any bullish signals to investors. We will analyze why Five Prime investors may still consider a stake in the business. Five Prime Therapeutics current chance of bankruptcy is under 41 percent. Will investors continue to be optimistic, or should we expect a sell-off?
Published over a week ago
View all stories for Five Prime | View All Stories
Are investors happy with Five Prime (NASDAQ:FPRX) basic indicators?
Five Prime has performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.2363, which means not very significant fluctuations relative to the market. Let's try to break down what Five Prime's beta means in this case. As returns on the market increase, Five Prime returns are expected to increase less than the market. However, during the bear market, the loss on holding Five Prime will be expected to be smaller as well. Although it is extremely important to respect Five Prime Therapeutics historical returns, it is better to be realistic regarding the information on equity current trending patterns. The philosophy towards predicting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By reviewing Five Prime Therapeutics technical indicators, you can presently evaluate if the expected return of 0.14% will be sustainable into the future. Five Prime Therapeutics right now shows a risk of 4.77%. Please confirm Five Prime Therapeutics total risk alpha, downside variance, as well as the relationship between the Downside Variance and daily balance of power to decide if Five Prime Therapeutics will be following its price patterns.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Five Prime income statement, its balance sheet, and the statement of cash flows. Potential Five Prime investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Five Prime investors may use each financial statement separately, they are all related. The changes in Five Prime's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Five Prime's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Five Prime fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Five Prime performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Five Prime shares is the value that is considered the true value of the share. If the intrinsic value Five Prime is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Five Prime. Please read more on our fundamental analysis page.

What is Five Prime Asset Breakdown?

Five Prime Therapeutics reports assets on its Balance Sheet. It represents the amount of Five Prime resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Five Prime volatility, please check the breakdown of all its fundamentals

Are Five Prime Earnings Expected to grow?

The future earnings power of Five Prime involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Five Prime factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Five Prime stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Five Prime expected earnings.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Five Prime, but it might be worth checking our own buy vs. sell analysis

Five Prime Gross Profit

Five Prime Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Five Prime previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Five Prime Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Purchase by Bvf Partners L P of 25107 shares of Five Prime

Legal trades by Five Prime insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Five Prime insider trading alert for perchase of common stock $0.001 par value by Bvf Partners L P, the corporate stakeholder, on 8th of October 2020. This event was filed by Five Prime Therapeutics I with SEC on 2020-10-08. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Five Prime Indicators

There are few distinct groups of Five Prime stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Five Prime is distributed among investors.

Ownership Allocation

Five Prime holds a total of thirty-six million six hundred thirty thousand outstanding shares. The majority of Five Prime Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Five Prime Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Five Prime. Please pay attention to any change in the institutional holdings of Five Prime Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
23.39%
Institutions
73.55%
Retail Investors23.39
Insiders3.06
Institutions73.55

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Five Prime has an asset utilization ratio of 3.29 percent. This suggests that the company is making $0.0329 for each dollar of assets. An increasing asset utilization means that Five Prime Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
220 M
Assets Non Current
62 M
Current Assets219.98 Million76.3
Assets Non Current61.96 Million21.49
Tax Assets6.37 Million2.21

Over 3 percent rise for Five Prime. What does it mean for investors?

The variance is down to 20.14 as of today. Five Prime Therapeutics exhibits very low volatility with skewness of 0.55 and kurtosis of 0.76. However, we advise investors to further study Five Prime Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Takeaway on Five Prime Investment

While some other entities under the biotechnology industry are still a bit expensive, Five Prime may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Five Prime valuation and our trade advice on Five Prime is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Five Prime.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Five Prime Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com